Latest Monoclonal antibodies Stories

Antibody Technologies and Attrition Rates - An Industry Analysis 2013

2013-04-16 12:26:37

DUBLIN, Ireland, April 16, 2013 /PRNewswire/ -- Research and Markets announces the addition of "Antibody Technologies and Attrition Rates - an industry analysis 2013 [http://www.researchandmarkets.com/research/7rg77r/antibody ]" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report Antibody Technologies and Attrition Rates - an industry analysis 2013 is based on the identification of the antibody generation technologies of...

Xencor Licenses Xtend(TM) Therapeutic Protein Half-life Extension Technology to CSL

2013-04-16 08:28:59

MONROVIA, Calif. and MELBOURNE, Australia, April 16, 2013 /PRNewswire/ -- Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend technology to optimize the performance of CSL's monoclonal antibodies. Under the agreement CSL will be granted an exclusive license to utilize Xencor's proprietary Xtend(TM) half-life extension technology in its program against an undisclosed target. Xencor will...

Covagen Names Elias Papatheodorou Chief Business Officer

2013-04-15 04:20:52

ZURICH-SCHLIEREN, Switzerland, April 15, 2013 /PRNewswire/ -- Covagen today announced the expansion of its senior management team with the appointment of Elias Papatheodorou as chief business officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements. Prior to joining Covagen, Mr. Papatheodorou was senior vice president business development and operations at Medigene where he led the...

Igenica Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer

2013-04-09 12:29:00

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer. Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences,...

Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018

2013-04-09 08:31:40

Surveyed Payers Expect to Restrict the Prescribing of Emerging Biologics Through Controls Similar to Xolair, Limiting Patient Access, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with...

OriGene to Acquire SDIX's Life Science Business Assets

2013-04-08 12:27:53

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX(TM) (NASDAQ: SDIX), a leading provider of biotechnology-based products and services. (Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO) "We anticipate the...

Surveyed U.S. Neurologists Would Prescribe Biogen Idec's Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)

2013-04-08 08:31:12

An Increased Effect in Preventing Sustained Disability Progression is One of the Greatest Unmet Needs in RR-MS, According to a New Report from Decision Resources BURLINGTON, Mass., April 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicated that they would prescribe Biogen Idec's Tecfidera to 20 percent of their patients with relapsing-remitting...

Studies show increasing costs and potential for significantly higher use of specialty drugs to treat inflammatory autoimmune conditions

2013-04-04 08:29:34

Three new studies review use, comparative effectiveness and cost SAN DIEGO, April 4, 2013 /PRNewswire/ -- In recent years, biologic anti-inflammatory (BAI) specialty medications used to treat autoimmune inflammatory conditions such as rheumatoid arthritis (RA), psoriasis and Crohn's disease, have seen double-digit percentage price increases. The potential exists to treat many more patients than are currently receiving a BAI medication, according to new studies presented today by...

Emerging Precision Medicine Powerhouse Changes Name to Increase Visibility and Overall Awesomeness

2013-04-01 08:23:18

LOS ANGELES, April 1, 2013 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody technology, today announced that it has changed its name to AmaginAb. During a 'strategy meeting' at a recent employee team-building event, the Company's management belatedly realized that most of the important companies in the biotechnology space begin with the letter 'A'. "It became clear by the third hot chocolate one evening during our...

Market Analysis: Biomaterials and Engineered Protein

2013-03-28 16:24:33

ReportsnReports.com offers 2013 market research reports on polymer biomaterials and protein engineering industry products like monoclonal antibodies, insulin analog and modified EPO. DALLAS, March 28, 2013 /PRNewswire-iReach/ -- Market Research on Biomaterials and Protein Engineering Industry Products with Technology and Applications (Photo: http://photos.prnewswire.com/prnh/20130328/CG85250) The global biomaterials market is poised to grow at a CAGR of 15% from 2012 to 2017 to...